Can Galmed’s dissolving Aramchol film turn a former liver drug into a Parkinson’s contender?
Galmed’s Aramchol film may simplify Parkinson’s dosing, but clinical proof and regulatory clearance remain ahead. See what matters next.
Pharma & Biotech
Pharma & Biotech
Zambon’s Hopledo wins CHMP backing, but can fewer daily doses reshape Parkinson’s care?
See how Zambon’s Hopledo could change Parkinson’s motor fluctuation care in Europe after a positive CHMP opinion, and what risks remain.
Medical Devices & Diagnostics
Insightec’s Parkinson’s study shows motor gains, but bilateral treatment raises safety concerns
Staged bilateral focused ultrasound reduced Parkinson’s motor complications without implanted hardware, but persistent speech, gait and balance effects narrow the patients most likely to benefit.
Pharma & Biotech
Acurex Biosciences moves 15-lipoxygenase program closer to Parkinson’s disease clinical testing
Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.
Pharma & Biotech
Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.
Pharma & Biotech
Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.
Pharma & Biotech
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Pharma & Biotech
What Matricelf’s Parkinson’s spinout reveals about the future of cell based neurodegeneration therapies
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
Pharma & Biotech
Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.
Pharma & Biotech
How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.